Biotech Values

[dewophile]

i think you are more confident of a non-approval for t-enox than mnta management :)

in all seriousness if mnta really knew m-enox would retain sole generic status there would be no reason for this offering - even if they wanted to build out manufacturing for an FoB program*, which is costly, they would monetize some portion of lovenox revenue stream

*contracting this out may be more complicated for mnta because it may mean they have to transfer out IP related to the manufacturing